Testing short courses of strong radiation for solid tumors, including glioblastoma
Original title: Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is listed, so this is still a study in people, not proven care.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests radiation given in fewer but stronger doses.
Who this trial is for. This study is for people with solid tumors. Aim 2 is for people with glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary. It tests radiation given in fewer, stronger doses. Doctors also want to learn how that radiation works with the immune system.
Where it stands. The trial has not reported results. Teams are measuring how well this radiation works. They are also tracking side effects and changes in the immune system. The answers are not in yet.
What this means, and what it doesn't
What it could mean: Shorter, stronger radiation is being studied for brain tumors. Doctors at the three hospitals plan to use the same methods. If this sounds like your situation, you can ask your care team about it.
What it doesn't mean: This does not mean the treatment is proven. A trial is a test, not care your doctor can give you today. Joining one is not a promise that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.